• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
GYN

ACOG Recommendations: Management of Postmenopausal Osteoporosis

image_pdfFavoriteLoadingFavorite

SUMMARY:

Osteoporosis is a common disease that can result in bone fractures. Through screening, risk assessment, and pharmacologic treatment, fractures can be prevented. DEXA scans should be used for screening starting at age 65 for most women. Biphosphonates are the first line therapy for patients found to be high risk patients and should be used for most postmenopausal patients

Diagnosis

  • Dual Energy X-Ray (DEXA) is preferred method
    • Hip and lumbar bone mineral density measurements most accurate
    • Osteoporosis diagnosed with T Score ≤–2.5
    • T-score between −1.0 and −2.5 and increased risk of fracture using a formal clinical risk-assessment tool such as the US Fracture Risk Assessment (FRAX) tool
  • Clinically diagnosed if patient has a fragility fracture
    • Fracture occurs after a fall at less than standing height
    • Usual site: Hip | Humerus | Rib | Pelvis | Wrist | Spine
    • Includes asymptomatic vertebral fracture

Treatment

Lifestyle Modifications

  • Weight bearing exercises
  • Adequate intake of vitamin D and calcium
    • Calcium RDA:
      • Age 19 to 50 years: 1000 mg per day
      • >50 years: 1200 mg per day 
    • Vitamin D RDA
      • ≤70 years: 600 IU
      • >70 years: 800 IU per day
  • Fall prevention strategies

Pharmacotherapy: Work-up and Candidates for Treatment

  • Patient with high risk of fracture should be treated pharmacologically
  • Before starting pharmacotherapy, patients should be evaluated for secondary causes of bone loss
    • HIV/AIDs | Anorexia | Diabetes | Hyperparathyroidism | Renal impairment | Rheumatoid arthritis | Turner’s syndrome | Vitamin D Deficiency | Medication induced
  • Secondary Osteoporosis Evaluation
    • Complete blood count | Metabolic profile | 24-hour collection for Ca, Na, Cr excretion | Liver function tests | TSH with or without free T4 | 25-hydroxyvitamin D

Pharmacotherapy Options

  • Bisphosphonates
    • First line therapy
    • Discontinue in patients who are at low-to-moderate risk if stable after
      • 5 years of treatment with oral bisphosphonates or
      • 3 years of treatment with IV zoledronic acid
  • Denosumab
    • Use if a patient prefers less frequent medication administration
    • 6-month subcutaneous administration
    • Patients who discontinue denosumab therapy should be transitioned to treatment with another antiresorptive agent
  • Raloxifene
    • Can be used for postmenopausal women who
      • Are at increased risk of vertebral fracture and breast cancer
      • Have low risk of venous thromboembolism
      • Have no significant vasomotor symptoms
  • Teriparatide and abaloparatide
    • Parathyroid hormone analogs
    • Can be used in postmenopausal women for up to 2 years  
      • Who are at very high risk of fracture
      • Continue to sustain fractures
      • Have significant bone loss while taking antiresorptive therapy
  • Romosozumab
    • Sclerostin-binding inhibitor
    • Can be used in postmenopausal women for up to 1 year
    • Should meet the following criteria
      • Not at increased risk of cardiovascular disease/stroke and have high risk of fracture or
      • Other treatments have not been effective

Note: If unable to tolerate pharmacologic therapy, patient should consume the recommended daily allowance of calcium and vitamin D, ideally through diet although supplementation acceptable

Treatment Monitoring

  • DXA testing every 1 to 3 years if patient is on pharmacotherapy until findings are stable

KEY POINTS:  

  • DEXA scan T score of ≤–2.5 gives diagnosis of osteoporosis
  • Evaluate all patients for secondary causes of bone loss before starting pharmacotherapy
  • Breast cancer patients/survivors are at high risk of osteoporosis development if they were treated with chemotherapy or aromatase inhibitors
  • Pharmacologic treatment is recommended for all patients at high risk of fracture
  • Bisphosphonates should be initial therapy for most postmenopausal patients
  • DXA testing every 1 to 3 years if patient is on pharmacotherapy until findings are stable

Learn More – Primary Sources:

ACOG Clinical Practice Guideline 2: Management of Postmenopausal Osteoporosis

FRAX® Fracture Risk Assessment Tool

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All GYN Posts
Next >

Related ObG Topics:

USPSTF Recommendations: Screening for Osteoporosis to Prevent Fractures
Hip Fractures in Older Women: Who is at Risk and Would Benefit Most from Treatment?
ARCH Study Results: Does Romosozumab Prevent Fracture in Women with Osteoporosis?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site